|1.||Miller, Ryan: 1 article (12/2014)|
|2.||Vardeny, Orly: 1 article (12/2014)|
|3.||Solomon, Scott D: 1 article (12/2014)|
|4.||Park, Timothy: 1 article (04/2011)|
|5.||Olsufka, Rachael: 1 article (04/2011)|
|6.||Cheruvu, Madhavi: 1 article (04/2011)|
|7.||Lane, Cassie E: 1 article (04/2011)|
|8.||Klein, Uwe: 1 article (04/2011)|
|9.||Sandvik, Erik R: 1 article (04/2011)|
|10.||Armstrong, Scott R: 1 article (04/2011)|
03/01/1999 - "In this multi-centre double-blind placebo controlled study, 60 patients with NYHA Class I-III heart failure were randomised to candoxatril 200 mg b.d. "
01/01/1996 - "The aim of the study was to investigate the haemodynamic and endocrine effects of the NEP inhibitor candoxatril in patients with congestive heart failure (CHF). "
01/01/1999 - "It further describes the pharmacokinetics and pharmacodynamics of candoxatril in normal healthy individuals and in patients with chronic cardiac failure. "
01/01/1999 - "The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man."
12/01/1993 - "Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure."
|2.||Hypertension (High Blood Pressure)
12/01/1993 - "Inhibition of endopeptidase EC 220.127.116.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension."
04/01/1993 - "Two groups of 12 white male patients with essential hypertension were treated with candoxatril at 25 mg every 12 h (group 1) or at 200 mg every 12 h (group 2) for 5 days in double-blind, placebo-controlled, crossover studies. "
03/01/1992 - "Candoxatril in a single dose caused no adverse effects in essential hypertension. "
04/01/1993 - "Candoxatril augments the effects of ANF and lowers blood pressure in patients with hypertension. "
07/01/1992 - "To examine the efficacy and tolerability of the neutral endopeptidase inhibitor, candoxatril (UK 79,300) as monotherapy in essential hypertension. "
09/01/1998 - "Myocardial infarction was induced by left coronary artery ligation in rats and they were treated either with candoxatril (10mg/kg per day) or a vehicle for up to 4 weeks. "
09/01/1998 - "The effects of candoxatril on hemodynamic parameters and cardiovascular hypertrophy were evaluated in the rat model of myocardial infarction. "
09/01/1998 - "These data indicate that inhibition of neutral endopeptidase by candoxatril at a dose of 10 mg/kg per day did not oppose cardiac hypertrophy in the rat model of myocardial infarction in spite of significant neutral endopeptidase inhibition."
02/01/2004 - "Four weeks after myocardial infarction, B(2)-/- mice and B(2)+/+ mice were started on vehicle, ACEi (ramipril, 2.5 mg/kg/d), NEPi (candoxatril, 20 mg/kg/d) or VPi (omapatrilat, 50 mg/kg/d), which was continued for 20 weeks. "
|1.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|3.||Neprilysin (Neutral Endopeptidase)
|4.||Atrial Natriuretic Factor (ANF)
|7.||Brain Natriuretic Peptide (Natrecor)
|10.||Type 1 Angiotensin Receptor